Loading clinical trials...

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGPhase 2NCT06696183

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for inten...

Lead sponsor: Technische Universität Dresden•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Prof. Dr. Christoph Röllig, MD, MSc

CONTACT

+49 351 458 4190 sequence@ukdd.de

Related studies

RECRUITINGPhase 1

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676 · High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), and more

RECRUITING

Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

NCT06782971 · AML - Acute Myeloid Leukemia

Not Yet RecruitingEARLY Phase 1

CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia

NCT07201727 · AML - Acute Myeloid Leukemia

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 29, 2025Terms

Trial snapshot

StatusRECRUITING

PhasePHASE2

Enrollment60

Start dateApr 2025

Last updatedMay 29, 2025

Condition

AML - Acute Myeloid Leukemia

Locations shown

Technische Universität Dresden

Dresden

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 29, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions